Cellular immunity delimits adenoviral gene therapy strategies for the treatment of neoplastic diseases

被引：28

作者：

DeMatteo, RP ^{[1
]}

Yeh, H ^{[1
]}

Friscia, M ^{[1
]}

Caparrelli, D ^{[1
]}

Burke, C ^{[1
]}

Desai, N ^{[1
]}

Chu, G ^{[1
]}

Markmann, JF ^{[1
]}

Raper, SE ^{[1
]}

Barker, CF ^{[1
]}

机构：

[1] Hosp Univ Penn, Dept Surg, Philadelphia, PA 19104 USA

来源：

ANNALS OF SURGICAL ONCOLOGY | 1999年 / 6卷 / 01期

关键词：

adenovirus; gene therapy; immune response; cancer;

D O I：

10.1007/s10434-999-0088-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Adenoviral gene therapy is a promising new approach for the treatment of neoplastic diseases. To design rational clinical trials and distinguish the effects of therapeutic transgene expression From those caused by viral infection alone, the immune response to the vector must be understood. In these experiments, we further define cellular immunity to recombinant adenovirus. Methods: The immune response to hepatic adenoviral gene transfer was studied in infected mice by depleting T cells with an anti-CD3 antibody, measuring splenocyte cytokine production, determining the impact of transgene expression on inflammation, and assessing Liver MHC protein expression. Results: The cellular immune response to recombinant adenovirus is (I) averted by T lymphocyte depletion, (2) marked by a T(H)1 response with increased IL-2 production, (3) directed against both the transgene product and viral proteins, and (4) associated with increased hepatocyte MHC Class I expression. Conclusions: It is necessary to take into consideration the constraints imposed by the immunogenicity of recombinant adenovirus and its transient transgene expression in the clinical application of adenoviral gene transfer for the treatment of cancer.

引用

页码：88 / 94

页数：7

共 30 条

[1] ADMINISTRATION OF AN ADENOVIRUS CONTAINING THE HUMAN CFTR CDNA TO THE RESPIRATORY-TRACT OF INDIVIDUALS WITH CYSTIC-FIBROSIS [J].

CRYSTAL, RG ;

MCELVANEY, NG ;

ROSENFELD, MA ;

CHU, CS ;

MASTRANGELI, A ;

HAY, JG ;

BRODY, SL ;

JAFFE, HA ;

EISSA, NT ;

DANEL, C .

NATURE GENETICS, 1994, 8 (01) :42-51

[2] CELLULAR AND HUMORAL IMMUNE-RESPONSES TO ADENOVIRAL VECTORS CONTAINING FACTOR-IX GENE - TOLERIZATION OF FACTOR-IX AND VECTOR ANTIGENS ALLOWS FOR LONG-TERM EXPRESSION [J].

DAI, YF ;

SCHWARZ, EM ;

GU, DL ;

ZHANG, WW ;

SARVETNICK, N ;

VERMA, IM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (05) :1401-1405

[3] Engineering tissue-specific expression of a recombinant adenovirus: Selective transgene transcription in the pancreas using the amylase promoter [J].

DeMatteo, RP ;

McClane, SJ ;

Fisher, K ;

Yeh, H ;

Chu, G ;

Burke, C ;

Raper, SE .

JOURNAL OF SURGICAL RESEARCH, 1997, 72 (02) :155-161

[4] Long-lasting adenovirus transgene expression in mice through neonatal intrathymic tolerance induction without the use of immunosuppression [J].

DeMatteo, RP ;

Chu, G ;

Ahn, M ;

Chang, E ;

Barker, CF ;

Markmann, JF .

JOURNAL OF VIROLOGY, 1997, 71 (07) :5330-5335

[5]

Dematteo RP, 1996, GENE THER, V3, P4

[6] Immunologic barriers to hepatic adenoviral gene therapy for transplantation - Cellular and humoral responses limit transgene expression in mouse liver [J].

DeMatteo, RP ;

Chu, G ;

Ahn, M ;

Chang, E ;

Burke, C ;

Raper, SE ;

Barker, CF ;

Markmann, JF .

TRANSPLANTATION, 1997, 63 (02) :315-319

[7] ABLATION OF E2A IN RECOMBINANT ADENOVIRUSES IMPROVES TRANSGENE PERSISTENCE AND DECREASES INFLAMMATORY RESPONSE IN MOUSE-LIVER [J].

ENGELHARDT, JF ;

YE, XH ;

DORANZ, B ;

WILSON, JM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (13) :6196-6200

[8]

FREEMAN SM, 1993, CANCER RES, V53, P5274

[9]

Hitt M M, 1997, Adv Pharmacol, V40, P137, DOI 10.1016/S1054-3589(08)60140-4

[10]

HUBER BE, 1993, CANCER RES, V53, P4619

← 1 2 3 →